Search Immortality Topics:

Page 4«..3456..1020..»


Category Archives: Pharmacogenomics

DATAR CANCER GENETICS ANNOUNCES FORAY INTO THE UNITED STATES WITH A $250M CONTRACT TO OFFER PIONEERING CANCER DETECTION LIQUID BIOPSIES – Yahoo…

LONDON, May 9, 2022 /PRNewswire/ -- Datar Cancer Genetics ("Datar"), a world-leading cancer research corporation today announced a $250 million contract with Artemis DNA, a leading USA-based diagnostic laboratory company that provides proprietary Next Generation Sequencing (NGS) genetic testing and diagnostic laboratory services for a wide variety of medical specialties, including cardiology, oncology, immunology, neurology, reproductive health and pharmacogenomics. Under the 5 years exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets.

Trucheck_Pragma_CancerTrack

The deal covers two solutions from Datar's cancer screening and diagnostic portfolio - Trucheck Pragma and Cancertrack. Trucheck Pragma is a non-invasive, blood-based screening test for Lung, Stomach, Colon, Pancreas, Prostate, Breast, and Ovarian cancers. Cancertrack is for the evaluation of response/resistance/recurrence during the management of cancer. The solutions will be presently offered as Laboratory Developed Tests (LDTs) in the USA.

In addition, Artemis DNA will provide Datar with high-complexity CLIA certified, CAP-accredited testing facilities in Texas and California to enable the commercial launch of various cancer screening and diagnostic tests developed by Datar.

"We are extremely delighted to offer our highly accurate cancer detection technology for the benefit of patients in the USA and Vietnam in partnership with Artemis DNA. Their marketing strength and experience will enable a seamless roll-out of our innovative, game-changing, life-saving Liquid Biopsies," commented Mr. Rajan Datar, Chairman of Datar Cancer Genetics. "We will continue to expand our offerings in the USA and European markets with high standards of accuracy and quality of service," he added.

"We are so excited to be able to offer the ground-breaking technologies to patients in the USA and Vietnam," commented Ms. Emylee Thai, Founder and CEO of Artemis DNA. "Datar Cancer Genetics continues to innovate and push the boundaries on what people thought was impossible when it comes to cancer screening, diagnosis and management. Artemis DNA is proud to be part of the pioneers to help change the landscape of early screening and diagnosis, as well as management of cancer, which will improve and save lives."

Story continues

Datar Cancer Genetics is a global oncology research and applications company specializing in non-invasive technologies for improved detection, treatment, and management of cancer. Datar's state-of-the-art facility is ISO, CAP-accredited and CLIA certified. Datar's tests for early detection of Breast and Prostate cancer have been granted 'Breakthrough Designation' by the US FDA. The Company serves cancer patients and suspected cases in the UK, European Union, United States, GCC, and India. The Company has already established an advanced research and testing facility at Guildford, UK, and is pursuing large clinical studies across various geographies to cover multiple cancers where there is a potential for cure with early detection. The Company also proposes to roll out multiple test centers globally.

CONTACT: Dr. Vineet Dattadrvineetdatta@datarpgx.com

Website: trucheck360.com

Image: https://mma.prnewswire.com/media/1813311/Trucheck_Pragma_CancerTrack.jpgLogo: https://mma.prnewswire.com/media/1572835/Datar_Cancer_Genetics_Logo.jpg

Datar_Cancer_Genetics_Logo

Cision

View original content:https://www.prnewswire.com/news-releases/datar-cancer-genetics-announces-foray-into-the-united-states-with-a-250m-contract-to-offer-pioneering-cancer-detection-liquid-biopsies-301542427.html

SOURCE Datar Cancer Genetics

View post:
DATAR CANCER GENETICS ANNOUNCES FORAY INTO THE UNITED STATES WITH A $250M CONTRACT TO OFFER PIONEERING CANCER DETECTION LIQUID BIOPSIES - Yahoo...

Posted in Pharmacogenomics | Comments Off on DATAR CANCER GENETICS ANNOUNCES FORAY INTO THE UNITED STATES WITH A $250M CONTRACT TO OFFER PIONEERING CANCER DETECTION LIQUID BIOPSIES – Yahoo…

Gut bacteria and stroke: What is the link? – Medical News Today

Past research links the health of the gut microbiome to various diseases, including inflammatory bowel disease, Alzheimers disease, and kidney disease.

Researchers from the Dr. Israel Fernndez Cadenas (PI) Group Stroke Pharmacogenomics and Genetics Laboratory have uncovered a link between certain bacteria in the gut microbiome associated with more severe stroke and negatively affecting post-stroke recovery.

Researchers presented the study on May 4, 2022, at the 2022 European Stroke Organisation Conference (ESOC).

What is the gut microbiome?

The gut microbiome refers to the trillions of bacteria and other microorganisms living within the intestinal tract of humans. Research shows these good bacteria play an important role in the bodys overall health, including boosting immunity and helping with digestion.

If the gut microbiome becomes unbalanced, it can harm the body. Stress, bad eating habits, and antibiotics can disrupt the gut microbiome. When this happens, the body becomes vulnerable to diseases, including those related to inflammation, such as rheumatoid arthritis and heart disease.

A stroke happens when blood is not able to reach the brain. If blood flow to the brain becomes blocked, oxygen and vital nutrients cannot get to the brain, which can cause brain cells to die.

Data shows that about 13 million people globally experience a stroke each year, and about 5.5 million people die from strokes.

There are two main types of strokes:

In this new study presented at the 2022 European Stroke Organisation Conference, a research team led by Miquel Lleds, lead researcher and Ph.D. student from the Stroke Pharmacogenomics and Genetics Laboratory Group at the Sant Pau Research Institute in Barcelona, Spain, studied fecal samples from 89 ischemic stroke patients.

The influence of the gut microbiome is a modifiable risk factor associated with the risk of stroke and with post-stroke neurological outcomes, Lleds explains. However, most research has previously been done in animal models. In this study, we took (fecal) samples the first samples taken after the event from 89 humans whod suffered an (ischemic) stroke. (Compared) with a control group, we were able to identify multiple groups of bacteria that were associated with a higher risk of (ischemic) stroke.

From their research, scientists identified multiple types of bacteria associated with an increased risk for ischemic stroke, including the bacteria Fusobacterium and Lactobacillus. They also found the bacteria Negativibacillus and Lentisphaeria were associated with a more severe stroke in the acute phase. And the bacteria Acidaminococcus led to poor post-stroke recovery after three months.

Acidaminococcus is an opportunistic pathogen, and this genus has already been related to a higher risk of stroke, Lleds told Medical News Today when asked why Acidaminococcus associates with poor functional outcomes at three months. He added that Acidaminococcus is a member of the family Veillonellaceae, known for producing succinate a compound linked to increased risk factors for cardiovascular disease.

Based on his teams research, Dr. Lleds said research on gut microbiota could have direct and simple applicability in the clinical field. If the evolution of patients with stroke is associated with the presence of a certain type of microbial flora, we could carry out clinical trials varying this microbial composition, he explained.

In other pathologies, clinical trials are being carried out in which researchers replace the intestinal flora through dietary changes or fecal transplantation from healthy individuals much more consistent in the long term, he continued. One way to do that is by using lyophilized compounds of microorganisms in capsules that are easy to ingest and that modify the intestinal flora.

And in regards to post-stroke recovery, Dr. Lleds said there are currently no specific neuroprotective treatments to prevent neurological worsening after stroke. The use of new therapies, such as changes in the microbiome through nutritional changes or fecal transplantation, could be useful to improve post-stroke evolution, he added.

MNT also spoke about this study with Dr. Reza Shahripour, a board certified vascular neurologist at Providence Saint Johns Health Center in Santa Monica, CA. He says the label cryptogenic stroke is used for 30 to 35 percent of stroke cases where there is no known cause for the condition.

We dont know whats the etiology and the patient doesnt have any atherosclerosis disease, no cardioembolic source, he explained. If we believe that inflammation of these kinds of microbes in the gut could be the source of inflammation, we have a reason for that type of stroke.

Additionally, Dr. Shahripour said there are recurrent stroke cases in people taking antiplatelet or anticoagulant drugs.

If there is a risk factor of (the) microbiome in the gut, if we can address it before another stroke, we can decrease the (recurrence) of stroke in the future, he added.

Link:
Gut bacteria and stroke: What is the link? - Medical News Today

Posted in Pharmacogenomics | Comments Off on Gut bacteria and stroke: What is the link? – Medical News Today

Clinical Laboratory Tests Market To Witness Revenue Surge Reaching $304.9 Billion By 2027, Driven By Rising Investments in Diagnosing Target Diseases…

According to a new report published by Grand View Research, increasing prevalence of chronic diseases and rising awareness among health-conscious population have fueled the growth of the global clinical laboratory tests industry.

Clinical Laboratory Tests Industry Overview

The global clinical laboratory tests market size was valued at USD 176.7 billion in 2019 and is expected to reach USD 304.9 billion by 2027, registering a CAGR of 7.1% over the forecast period. Increasing prevalence of chronic diseases and rising awareness among health-conscious population have fueled the growth of the overall market.

The demand for clinical laboratory tests is driven by growing investments in diagnosing target diseases such as cardiovascular disorders, tuberculosis, and diabetes. Clinical laboratory tests help diagnose diabetes mellitus. According to an article published by the International Diabetes Federation in 2019, around 463 million adults were living with diabetes, and by 2045 it is estimated to reach 700 million globally.

Gather more insights about the market drivers, restrains and growth of the Global Clinical Laboratory Tests Market

Increasing geriatric population is anticipated to drive the overall market for clinical laboratory tests. According to the data published by the World Population Prospects: the 2019 Revision, around one in 11 people were aged over 65 years in 2019, and by 2050, it is estimated that approximately one in 6 people in the world will be aged 65 years and above. Clinical laboratory tests are increasingly used to diagnose age-related diseases.

Moreover, growing rate of insufficient exercise, consumption of unhealthy food, and the subsequent rise in cases of obesity are expected to increase the prevalence of various chronic diseases. Rising awareness of the necessity of regular body profiling among healthcare professionals and patients globally is expected to increase the demand for clinical laboratory tests.

Clinical Laboratory Tests Market Segmentation

Based on the Type Insights, the market is segmented into Complete blood count, HGB/HCT, Basic metabolic panel, BUN creatinine tests, Electrolytes testing, HbA1c tests, Comprehensive metabolic panel, Liver panel, Renal panel, Lipid panel.

Based on the End-use Insights, the market is segmented Central Laboratories and Primary Clinics.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Browse through Grand View Researchs Clinical Diagnostics IndustryResearch Reports.

Market Share Insights

Key Companies Profile:

Key companies are focusing on strategic partnerships, mergers, and acquisitions to increase their presence in the market for clinical laboratory tests.

Order a free sample PDF of the Clinical Laboratory Tests Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research is a full-time market research and consulting company registered in San Francisco, California. The company fully offers market reports, both customized and syndicates, based on intense data analysis. It also offers consulting services to business communities and academic institutions and helps them understand the global and business scenario to a significant extent. The company operates across multitude of domains such as Chemicals, Materials, Food and Beverages, Consumer Goods, Healthcare, and Information Technology to offer consulting services.

Web: https://www.grandviewresearch.com

Media ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist U.S.A.Email: Send EmailPhone: 1888202951Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United StatesCity: San FranciscoState: CaliforniaCountry: United StatesWebsite: https://www.grandviewresearch.com/industry-analysis/clinical-laboratory-tests-market

Read this article:
Clinical Laboratory Tests Market To Witness Revenue Surge Reaching $304.9 Billion By 2027, Driven By Rising Investments in Diagnosing Target Diseases...

Posted in Pharmacogenomics | Comments Off on Clinical Laboratory Tests Market To Witness Revenue Surge Reaching $304.9 Billion By 2027, Driven By Rising Investments in Diagnosing Target Diseases…

MGI announces partnership with Nalagenetics to advance pharmacogenomics in Singapore and Indonesia – AsiaOne

The partnership will address some critical issues in pharmacogenetic assay through sequencing workflows improvement SINGAPORE - Media OutReach - 21 April 2022 - MGI , a company committed to being a world-leading life science innovator, today announced a partnership with Nalagenetics (NALA) to co-develop low coverage whole genome sequencing for risk prediction and pharmacogenomics through optimizing Next Generation Sequencing (NGS) workflow based on MGI's sequencing devices and products*.

The collaboration aims to use NALA' Clinical Decision Support, a software medical device, to be able to analyze whole genome sequencing data sets generated by MGI's DNBSEQTM sequencing platform*, and generate clinical-grade reports for pharmacogenomics and polygenic risk scores. Although NGS has been known to be an effective way to capture a large amount of genomic information to guide and tailor clinical management and treatment,[1] NGS workflows are complicated and not trivial to adopt in clinical settings. NALA is dedicated to help implement clinical genetic testing in Southeast Asia with strong expertise in pharmacogenetics, assay development, and AI-linked genetics analysis for pharmacological phenotypes and risk prediction.

"We see more and more hospitals adopting sequencing for personalization of medicine in oncology, cardiovascular conditions, and others. One of the biggest challenges is recommending follow up action that makes sense for the local market, for example list of alternative therapies and screening procedures that lead to cost-effectiveness. We are glad to work with MGI to co-develop products and offer services to answer local needs," said Levana Sani, CEO of Nalagenetics.

[1] Gagan and Van Allen Genome Medicine (2015) 7:80 DOI 10.1186/s13073-015-0203-x. Accessed at https://genomemedicine.biomedcentral.com/track/pdf/10.1186/s13073-015-0203-x.pdf

MGI Tech Co., Ltd. (MGI), an affiliate of BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments*, reagents*, and related products to support life science research, agriculture, precision medicine and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2020, MGI has a footprint that spans across more than 70 countries and regions, serves over 1,000 international users and employs more than 1,700 professionals globally, around 33% of which are R&D personnel. For more information, please visit the MGI website or connect on Twitter , LinkedIn or YouTube .

*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland and Portugal.

#MGI

Nalagenetics is a biotechnology technology company focusing on personalized screening and intervention. Nalagenetics aims to provide affordable and actionable end-to-end genetic testing that is relevant to local populations by working with hospitals and labs. The company's main product, Clinical Decision Support, allows providers to generate clinical-grade genetic reports from raw genetic data files and clinical input. Nalagenetics has presence in Southeast Asia and Europe. For more information, please visit http://www.nalagenetics.com .

#Nalagenetics

The issuer is solely responsible for the content of this announcement.

See the original post:
MGI announces partnership with Nalagenetics to advance pharmacogenomics in Singapore and Indonesia - AsiaOne

Posted in Pharmacogenomics | Comments Off on MGI announces partnership with Nalagenetics to advance pharmacogenomics in Singapore and Indonesia – AsiaOne

Talk on the Secrets of Fruit-Eating Mammals Wins 2022 UCSF Grad Slam – University of California, San Francisco

Wei Gordon, Tetrad, delivered her first-prize winning research at Grad Slam 2022, titled, Uncovering the Sweet Secrets of Fruit-Eating Mammals, at the Grad Divisions annual student research competition held for the first time in three years, in Byers Hall, at the Mission Bay campus. Image by Susan Merrell

The prevalence of sugary foods in our diets has contributed to the rise of diabetes now the eighth leading cause of death in the United States. Human bodies arent equipped to handle so much sugar, but mammals adapted for sugary diets, like fruit-eating bats and primates have the ability to lower their blood sugar faster.

Wei Gordon, a PhD student in UC San Franciscos Tetrad Program, is studying the genetic secrets of these sugar-eating animals and her talk on this work won first prize in this years UCSF Grad Slam.

She was among nine finalists in the sixth annual UCSF Grad Slam, held March 31 after a two-year hiatus due to the pandemic competing to inform and entertain with three-minute talks based on their own research. Their talks reflected the broad range of science research conducted at UCSF, from designing culturally competent care for COVID-19, to fighting bacteria with phages, to understanding the misfolded proteins that lead to dementia.

The live event was held in front of a limited but enthusiastic audience in Byers Auditorium and live-streamed online. Nicquet Blake, PhD, dean of the Graduate Division and vice provost of Student Academic Affairs, provided opening remarks and awarded prizes, and Elizabeth Silva, PhD, associate dean for graduate programs, emceed the program. A panel of judges selected first-, second-, and third-prize winners. Both in-person and online audiences were able to vote for the Peoples Choice winner.

Gordon, who is a PhD student in the lab of Nadav Ahituv, PhD, took home the $4,000 first-place prize with her talk, Uncovering the Sweet Secrets of Fruit-Eating Mammals, which described her research into the thousands of DNA mutations present only in fruit-eating mammals. In particular, she is focusing on so-called gene regulatory regions, which serve as the conductors directing the work of genes, or the instruments. She impressed the judges with her confident delivery, which she credited to her love of theater.

I know that Im a very expressive person, so I tried to make sure to have some fun in the presentation, she said. The process of preparing for Grad Slam showed her the difficulty of breaking down scientific terms and also the power of metaphors to communicate complex ideas, she said.

Gordon will go on to represent UCSF at the UC system-wide Grad Slam event on May 6.

Coming in second place, with a prize of $2,000, was Rachel Nakagawa, a PhD student in the Biomedical Sciences Program. In her talk, Deconstructing Tumor Cell Interactions, Nakagawa outlined the challenge of treating solid tumor cancers, which consist of diverse communities of cells that can work together to thwart therapies. Parsing these interactions is like trying to eavesdrop at a crowded party, she said, so she is deconstructing them into simpler parts that could one day be targeted by drugs.

Luca Abascal Miguel, a PhD student in the Global Health Sciences Program, won the third-place spot with her talk, No le Pidas Peras al Olmo/Dont Ask the Elm Tree for Pears, the first UCSF Grad Slam talk given in Spanish. Abascal Miguel described the language, cultural and socioeconomic barriers that have contributed to COVID-19s disproportionate impact on the Latinx community in California. Studying these barriers allowed her to help develop effective targeted interventions for these communities.

The Peoples Choice award chosen by the live and remote viewing audiences went to Gokul Ramadoss, a PhD student in the Biomedical Sciences Program. In his talk, entitled Get Your Genes Tailored, he discussed his research into tools that could potentially treat the genetic typos that lead to devastating brain diseases like ALS.

These were the other finalists in this years live competition:

Neha Prasad (Chemistry and Chemical Biology), Our Friend, the Phage

Jack Stevenson (Chemistry and Chemical Biology), Learning the Tricks of the Most Valuable Protein: How Your Cells Decide to Divide

Megan Chong (Tetrad), Nobodys Perfect, But Dividing Cells Can Work It

Colin Germer (Pharmaceutical Sciences and Pharmacogenomics), Bursting Every Stress Bubble the Eye Can See

Kelly Montgomery (Chemistry and Chemical Biology), Paper Cranes and Paper Balls, Unfolding the Causes of Dementia

The finalists were selected by a panel of screening judges from entries submitted by video. from entries submitted by video.

The judges of the live event were Erin Allday, health reporter for the San Francisco Chronicle; Won HA, MA, UCSFs vice chancellor for communications; Catherine Lucey, MD, executive vice dean, vice dean for education and professor of medicine at the UCSF School of Medicine; Leticia Mrquez-Magaa, PhD, professor of biology and director of the Health Equity Research Laboratory at San Francisco State University; and Don Woodson, MEd, director of UCSFs Center for Science Education and Outreach.

All the finalists did an incredible job weaving in the creative use of metaphor and simile into their presentations on topics of such complexity, said Ha. He added that the judges aligned easily in their deliberations and decided on the winners unanimously.

Graduate Dean Nicquet Blake, PhD, who joined UCSF in December, remarked Grad Slam was the most fun Ive had since I arrived in San Francisco. I was told it was an awesome event, and it did not disappoint! It was gratifying to see our students creative approaches to making really important and timely research accessible for a general audience. In the process, they honed their science communication and advocacy skills that will serve them well no matter where their career path takes them. I congratulate all the finalists on a job well done, and I cant wait to tune in and cheer Wei on at the systemwide Grad Slam on May 6!

Read more:
Talk on the Secrets of Fruit-Eating Mammals Wins 2022 UCSF Grad Slam - University of California, San Francisco

Posted in Pharmacogenomics | Comments Off on Talk on the Secrets of Fruit-Eating Mammals Wins 2022 UCSF Grad Slam – University of California, San Francisco

2 Out of 3 Women with Depression or Anxiety Say TheyVe Reached Their Breaking Point, Yet More Than Half Wait a Year Before Seeking Treatment -…

Newswise Two out of three women diagnosed with depression or anxiety say they have reached or are approaching their breaking point regarding their mental health, according to the GeneSightMental Health Monitor, a new nationwide survey from Myriad Genetics, Inc. (NASDAQ: MYGN).

This breaking point can include a negative impact or a significant strain on anything from social life to caring for loved ones at home to professional obligations. Four out of 10 womenwithout a diagnosis ofdepression or anxiety say they have reached or are reaching this point.

When feeling overwhelmed, nearly three in four (72%) of women say they "just need to take a break, with 31% believing I need to try harder. Only 13% said they thought I should see a doctor when feeling overwhelmed.

Women often feel pressure to hold it all together and not admit when they are struggling, says Dr. Betty Jo BJ Fancher, a family medicine and psychiatric physician assistant with a doctorate of medical science and a masters in psychopharmacology. Yet, if you are sobbing on the floor of your shower, throwing things in anger or repeatedly screaming into a pillow, these are signals that you have crossed a line and should see a healthcare provider about your mental health.

Delaying mental health treatment is common among the women surveyed. In fact, more than half (51%) of women diagnosed with anxiety and/or depression waited at least one year before seeking treatment or never sought treatment at all.

The GeneSight Mental Health Monitor found that women are waiting more than a year longer than they should to get the mental health treatment they need, noted Rachael Earls, PhD, a medical science liaison with Myriad Genetics, makers of the GeneSight test. It is critical to receive treatment for mental health because we know that mental health conditions are highly comorbid with other physical diseases, such as cancer, stroke, heart disease. Why live with a mental health condition that can impact every aspect of your life until you reach a breaking point?

According to the survey, the top reasons women diagnosed with depression or anxiety delayed treatment are:

Will my concerns be validated or ignored?

The reluctance by some women to seek treatment may be rooted in how their mental health concerns have been received by family and friends.

Six in 10 of the women surveyed with depression or anxiety diagnosis say they have been ignored or dismissed by family, friends, and/or partners about their mental health concerns. Less than half of women (44%) say they talk to friends or family to relieve stress and anxiety.

I have friends who wont talk to their parents about how they are struggling because they are afraid of their parents reaction, says Ansley, daughter of Dr. Fancher and a senior at the University of Georgia, who has been diagnosed with depression, anxiety and ADHD. Therapy has helped me, so I know the benefits of talking to someone about your mental health. When friends or classmates say they are suffering with depression or anxiety, I encourage them to reach out to someone and get the help they need.

Despite available treatment options, fewer than two in 10 women believe they will ever be free from anxiety or depression symptoms.

Getting personalized treatment

Six in 10 women diagnosed with depression or anxiety agree that taking a prescription medication was the most helpful step in treating their anxiety or depression symptoms, more than any other action or treatment option offered in the survey, including therapy.

Only about 30% of women who have been prescribed psychiatric medication are aware of genetic testing that may help their physicians with prescribing decisions and only 8% of these respondents have had genetic testing. Yet, 67% of diagnosed women whose doctor didnotuse genetic testingsaid they wish their doctor had told them about and/or offered a genetic test that could provide information about how their genes may affect medication outcomes.

Dr. Fancher orders the GeneSight test to get personalized genetic information about her patients that helps her understand how they may metabolize or respond to certain medications commonly used to treat depression, anxiety, ADHD and other mental health conditions.

Having the genetic information from the GeneSight test at my fingertips to help inform my medication selection makes me a better provider, said Dr. Fancher.

Ansleys mental health provider also uses the GeneSight test. She made adjustments based on my results, and I am happy to say that everything is working really well, said Ansley.

For more information on how genetic testing can help inform clinicians on treatment of depression, anxiety, ADHD, and other psychiatric conditions, please visitGeneSight.com. To download graphics, a multimedia video and other information regarding the survey, please visitGeneSight.com/Mental-Health-Monitor.

About the GeneSightMental Health MonitorThe GeneSight Mental Health Monitor is a nationwide survey of U.S. adults conducted online by ACUPOLL Precision Research, Inc. from Feb. 25 March 11, 2022, among a statistically representative sample (n=1000) of adults age 18+. The survey included a representative sample of women diagnosed with depression and anxiety. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.

About the GeneSight TestThe GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patients genes may impact how they metabolize and/or respond to certain psychiatric medications. It has been given to more than 1.5 million patients by tens of thousands of clinicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. Learn more atGeneSight.com.

About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.Fast Companynamed Myriad among the Worlds Most Innovative Companies for 2022. For more information, visitwww.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

View original post here:
2 Out of 3 Women with Depression or Anxiety Say TheyVe Reached Their Breaking Point, Yet More Than Half Wait a Year Before Seeking Treatment -...

Posted in Pharmacogenomics | Comments Off on 2 Out of 3 Women with Depression or Anxiety Say TheyVe Reached Their Breaking Point, Yet More Than Half Wait a Year Before Seeking Treatment -…